Table 2.

Characteristics of the 60 drug and adverse reaction combinations from VigiBase that had been matched to THIN with enough leverage to be subject to chronograph evaluation

THIN characteristics					VigiBase characteristics
Chronograph pattern	No. of combinations	Median and range of first prescriptions*	Median and range of combinations within 1/12 months		No. combinations with serious terms** / new drug*** with serious term**	First‐year drug****
			1 month	12 months
Elevated exclusively after prescription	2	n = 2213 and 82 593	n = 1 and 1	n = 5 and 3	0/0	2002/1968
Elevated before prescription	24	M = 13 271	M = 7.5	M = 44	11/2	M = 1997
		R = 103–884 258	R = 0–521	R = 0–3037		R = 1968–2010
No elevation before or after prescription	34	M = 12 186	M = 2	M = 9	12/0	M = 1984
		R = 158–602 655	R = 0–120	R = 0–1170		R = 1968–2007

M = median, R = range.

^* First prescriptions denote prescriptions without any record of the same substance 13 months prior to the prescription in a patient's record history.

^** Serious terms are defined by using the WHO‐Adverse Reaction Terminology critical terms, that is, a subset of terms that have been classified to be indicative of a serious disease state.

^*** New drug is a drug entered in VigiBase for the first time during the past 5 years.

^**** First year when drug was entered in VigiBase.